Partnership Overview

Manchester University NHS Foundation Trust (MFT) has entered into a collaboration with Medtronic, a leading MedTech company, to co-develop solutions in artificial intelligence and robotic surgery.

Focus Areas

The partnership will concentrate on four key areas:

• Cardiovascular
• Neuroscience
• Medical Surgery
• Diabetes

Goals of the Collaboration

The collaboration aims to:

• Accelerate the development of technological solutions for unmet clinical needs.
• Benefit patients and healthcare providers on a global scale.

Statements from Leadership

Dr. Katherine Boylan, Deputy Managing Director of Research and Innovation at MFT, expressed enthusiasm about the partnership, stating:

“This agreement highlights our strong commercial relationship with Medtronic, allowing us to capitalize on opportunities to work together. Medtronic’s reputation as a leading HealthTech company aligns with MFT’s innovation ambitions.”

Dr. Matthew Williams-Gray, Senior Director of UK and Ireland at Medtronic, added:

“We are excited to strengthen our partnership with MFT through this collaboration, which aligns with our commitment to innovative health technology solutions that address unmet clinical needs.”

Support from Clinical Data Science Unit

The partnership will leverage MFT’s Clinical Data Science Unit, which transforms anonymized clinical data for public and professional benefit. This unit will support the development of innovations within a trusted research environment.

Infrastructure and Future Plans

The collaboration will also utilize MFT’s existing infrastructure, including the NIHR HealthTech Research Centre in Emergency and Acute Care. The focus will be on:

• Increasing remote patient monitoring.
• Enhancing community-based care.

Previous Successes

This agreement builds on a prior partnership that included the successful pilot of the TriageHP Plus remote heart monitoring pathway, which has significantly reduced hospitalizations due to heart failure.

Recognition and Future Outlook

In October 2024, the National Institute for Health and Care Excellence (NICE) recommended the use of this pathway for heart failure patients with cardiac implantable electronic devices. Additionally, Manchester’s Inward Investment Agency has launched a life sciences prospectus, emphasizing the region’s potential in the growing UK life sciences market.

Manchester is positioned as a key area for life sciences investment and innovation, aligning with the government’s goal to establish the UK as a global life sciences leader.